Lipoprotein(a) and its correlates in Japanese and U.S. population samples

Annals of Epidemiology

Volumn 6, Issue 4, 1996, Pages 324-330

  Iso, Hiroyasu ^a   Koike, Kazuko A ^a,b   Folsom, Aaron R ^c   Shimamoto, Takashi ^a   Sato, Shinichi ^d   Lida, Minoru ^d   Komachi, Yoshio ^e  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^c UNIVERSITY OF MINNESOTA   (United States)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

alcohol; Caucasians; cholesterol; coronary heart disease; cross culture comparison; fibrinogen; Japanese; Lipoprotein(a)

Indexed keywords

LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CORONARY RISK; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; JAPAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RACE DIFFERENCE; STATISTICAL ANALYSIS; UNITED STATES;

EID: 0030197499     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-2797(96)00050-6     Document Type: Article

References (55)

1. 1. Berg K, Dahlen G, Frick MH. Lp(a) lipoprotein and pre-beta-lipoprotein in patients with coronary heart disease. Clin Genet. 1974;6: 230-235.
2. 2. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51-61.
3. 3. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986; 256:2540-2544.
4. 4. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
5. 5. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
6. 6. Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis. 1986;59:249-257.
7. 7. Hearn JA, DeMaio SJ Jr, Roubin GS, Hammarstrom M, Sgoutas D. Predictive values of lipoprotein(a) and other serum lipoprotein(a) and other serum lipoproteins in angiographic diagnosis of coronary heart disease. Am J Cardiol. 1990;66:1760-1780.
8. 8. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population of middle aged men. BMJ 1990;301:1248-1251.
9. 9. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994; 24:444-453.
10. 10. Schreiner P, Chambless LE, Heiss G, et al. Lipoprotein[a] as a risk factor for incident coronary heart disease: Early results in the ARIC Study (abstract). Third International Conference on Preventive Cardiology. Oslo, Norway; 1993:58.
11. 11. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation. 1994;90:1688-1695.
12. 12. Schaefer E, Lamon-Fava S, Jennifer JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271:999-1003.
13. 13. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.
14. 14. Haffner SM, Moss SE, Klein BEK, Klein R. Lack of association between lipoprotein(a) concentrations and coronary heart disease mortality in diabetes: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Metabolism. 1992;41:194-197.
15. 15. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993; 270:2195-2199.
16. 16. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
17. 17. Pisa Z, Uemura K. Trends of mortality from ischaemic heart disease and other cardiovascular diseases in 27 countries. 1968-1977. World Health Stat Q. 1982;35:11-47.
18. 18. Iso H, Folsom AR, Sato S, et al. Plasma fibrinogen and its correlates in Japanese and US population samples. Arterioscler Thromb. 1993; 13:783-790.
19. 19. Iso H, Folsom AR, Koike KA, et al. Antigens of tissue plasminogen activator and plasminogen activator inhibitor. I. Correlates in non-smoking Japanese and Caucasian men and women. Thromb Haemost. 1993;70:475-480.
20. 20. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989:129; 687-702.
21. 21. Meade TW, Imerson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischemic heart disease. Lancet. 1987;2:986-988.
22. 22. Schriewer H, Assmann G, Sandkamp M. The relationship of lipoprotein(a) (Lp(a)) to risk factors of coronary heart disease: Initial results of the prospective epidemiological study on company employees in Westfalia. J Clin Chem Clin Biochem. 1984;22:591-596.
23. 23. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex and menopausal status on plasma lipoprotein (a) levels: The Framingham Offspring Study. Circulation. 1993;87:1135-1141.
24. 24. Nago N, Kayaba K, Hiraoka J, et al. Lipoprotein(a) levels in the Japanese population: Influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study. Am J Epidemiol. 1995;141:815-821.
25. 25. National Heart, Lung and Blood Institute. ARIC Manuals of Operations: 7. Blood Collection and processing; 8. Lipid and Lipoprotein Determination; 9. Hemostasis Determinations. Chapel Hill, NC: ARIC Coordinating Center. School of Public Health, University of North Carolina, 1987.
26. 26. Simons L, Freidlander Y, Simons J, McCallum J. Lipoprotein(a) is not associated with coronary heart disease in the elderly: Cross-sectional data from the Dubbo study. Atherosclerosis. 1993;99:87-95.
27. 27. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29:1075-1080.
28. 28. Nagele U, Hagele EO, Sauer G, et al. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Biochem. 1984;22:165-174.
29. 29. Manual of Laboratory Operations, Lipid Research Clinics Program: Lipid and Lipoprotein Analysis. Bethesda, MD: US Department of Health and Welfare Publication. 1974;1:75-628.
30. 2- precipitation (abstract). Clin Chem. 1982;28:1574.
31. 31. Nakamura M, Morita M, Yabuuchi E, et al. The evaluation and the results of cooperative cholesterol and triglyceride standardization program by WHO-CDC (in Japanese). Rinsho Byori 1982;30:325-332.
32. 32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
33. 33. Cloey T, Bachorik PS, Becker D, Finney C, Lowry D, Sigmund W. Reevaluation of serum-plasma differences in total cholesterol concentrations. JAMA. 1990;263:2788-2789.
34. 34. Clauss A. Gennungsphysiologische Schnellmethode sur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
35. 35. Owan I, Suda T. Strategy of osteoporosis therapy (in Japanese). J Clin Exp Med (IGAKU NO AYUMI). 1992;160:115-117.
36. 36. Yamasaki Y, Watarai T, Kawamori R, Kanda T, Kamada T. Lp(a) in Japanese diabetic children. Diabetes Care. 1992;15:112-1113.
37. 37. Boyer H, de Gennes JL, Truffert J, Chatellier G, Dairou F, Bruckert E. Lp(a) levels in different types of dyslipidemia in the French population. Atherosclerosis. 1990;85:61-69.
38. 38. Donders SH, Lustermans FA, van-Wersch JW. Low order correlations of lipoprotein(a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients. Blood Coagul Fibrinolysis. 1992;3:249-256.
39. 39. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91:191-205.
40. 40. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary heart disease. Eur Heart J. 1989;10:77-82.
41. 41. Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol. 1992;136:441-449.
42. 42. Haffner SM, Gruber KK, Morales PA, et al. Lipoprotein(a) concentrations in Mexican and non-Hispanic whites: The San Antonio Heart Study. Am J Epidemiol. 1992;136:1060-1068.
43. 43. Hajjar KA, Gavish D, Breslow JW, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
44. 44. Garcia Frade LJ, Alvarez JJ, Rayo I, et al. Fibrinolytic parameters and lipoprotein(a) levels in plasma of patients with coronary heart disease. Thromb Res. 1991;63:407-418.
45. 45. Yamashiro M, Seishima M, Kawade M. Alterations in serum Lp(a) lipoprotein concentrations in patients with hepatobiliary disorders. Jap J Clin Chem. 1987;16:79-84.
46. 46. Uternmann G. The mysteries of lipoprotein(a). Science. 1989; 246:904-910.
47. 47. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apoprotein B. Arteriosclerosis. 1985;5:265-272.
48. 48. Parra HJ, Luyeye I, Bouramoue C, Demarquilly C, Fruchart JC. Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta. 1987;168:27-31.
49. 49. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991;86:607-614.
50. 50. Haffner SM, Tuttle KR, Rainwater DL. Decrease of Lp(a) with improved metabolic control in subjects with insulin-dependent diabetes mellitus. Diabetic Care. 1991;14:302-307.
51. 51. Haffner SM, Morales PA, Stern MP, Gruber MK. Lp(a) concentrations in NIDDM. Diabetes 1992;41:1267-1272.
52. 52. Zimmet P. The global epidemiology of diabetes mellitus. Tohoku J Exp Med. 1983;141(Suppl):41-54.
53. 53. Blackburn H, Jacobs D. Sources of the diet-heart controversy: Confusion over population versus individual correlations. Circulation. 1984;70:775-780.
54. 54. Meada S, Abe A, Seishima M, Makino K, Noma A, Kawada M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atheroslerosis. 1989;78:145-150.
55. 55. Dahlen G. Lipoprotein(a) in relation to atherosclerotic diseases. Progr Clin Biol Res. 1988;255:27-36.